Cerity Partners’s Kronos Bio KRON Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-410,796
| Closed | -$339K | – | 2713 |
|
|
2025
Q1 | $339K | Hold |
410,796
| – | – | ﹤0.01% | 1961 |
|
|
2024
Q4 | $390K | Hold |
410,796
| – | – | ﹤0.01% | 1904 |
|
|
2024
Q3 | $411K | Hold |
410,796
| – | – | ﹤0.01% | 1886 |
|
|
2024
Q2 | $509K | Hold |
410,796
| – | – | ﹤0.01% | 1539 |
|
|
2024
Q1 | $534K | Hold |
410,796
| – | – | ﹤0.01% | 1569 |
|
|
2023
Q4 | $513K | Buy |
+410,796
| New | +$455K | ﹤0.01% | 1258 |
|
|
2023
Q3 | – | Sell |
-424,296
| Closed | -$730K | – | 1570 |
|
|
2023
Q2 | $730K | Hold |
424,296
| – | – | ﹤0.01% | 1032 |
|
|
2023
Q1 | $619K | Hold |
424,296
| – | – | ﹤0.01% | 1189 |
|
|
2022
Q4 | $687K | Hold |
424,296
| – | – | ﹤0.01% | 811 |
|
|
2022
Q3 | $1.42M | Hold |
424,296
| – | – | 0.02% | 437 |
|
|
2022
Q2 | $1.54M | Hold |
424,296
| – | – | 0.02% | 459 |
|
|
2022
Q1 | $3.07M | Hold |
424,296
| – | – | 0.05% | 253 |
|
|
2021
Q4 | $5.77M | Buy |
424,296
+394,296
| +1,314% | +$6.17M | 0.09% | 182 |
|
|
2021
Q3 | $629K | Hold |
30,000
| – | – | 0.01% | 422 |
|
|
2021
Q2 | $719K | Hold |
30,000
| – | – | 0.02% | 411 |
|
|
2021
Q1 | $878K | Buy |
+30,000
| New | +$879K | 0.02% | 363 |
|
Cerity Partners's KRON Position: Q2 2025 in Review
Cerity Partners sold out of Kronos Bio (KRON) in Q2 2025, closing a stake of 410,796 shares — an estimated $339K sold.
Cerity Partners first reported a position in KRON in Q1 2021 and held it in 16 quarters. The position peaked at $5.77M in Q4 2021. 0 funds tracked by Wall St. Rank hold KRON as of Q2 2025.
- Cerity Partners reported no remaining Kronos Bio position as of Q2 2025 after selling out during the quarter.
- Cerity Partners sold 410,796 Kronos Bio shares in Q2 2025, an estimated $339K.
- Cerity Partners first reported a position in Kronos Bio in Q1 2021 and held it in 16 quarters.
- Cerity Partners's Kronos Bio position peaked at $5.77M in Q4 2021.
- 0 funds tracked by Wall St. Rank held Kronos Bio as of Q2 2025.
Based on Cerity Partners's 13F filing for Q2 2025, filed 13 Aug 2025.